J. Fernando Arevalo, MD;
Reinaldo A. Garcia, MD |
HIV-related Vitreo-retinal Disease in Latin America
Volume 33, Number # 6, 2005 Series
J. Fernando Arevalo, MD;
Reinaldo A. Garcia, MD |
1. Tarantola DJ, Mann JM. Global expansion of HIV infection and AIDS. Hosp Pract (Off Ed). 1996;31(10):63-6, 69, 72-3.
2. Lewallen S, Courtright P. HIV and AIDS and the eye in developing countries: a review. Arch Ophthalmol 1997;115(10):1291-5.
3. Davis, JL. Foreword. In J. Fernando Ar�valo, editor. Manifestaciones Oculares del SIDA en el Nuevo Milenio,Texto y Atlas, 1st edition. Panam�: Highlights of Ophthalmology; 2004.p.Viii.
4. USPHS/IDSA Prevention of Opportunistic Infections Working Group. 1997 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus. USPHS/IDSA Prevention of Opportunistic Infections Working Group. MMWR Recomm Rep 1997;46(RR-12):1-46.
5. Jacobson MA, Zegans M, Pavan PR, O'Donnell JJ, Sattler F, Rao N, Owens S, Pollard R. Cytomegalovirus retinitis after initiation of highly active antiretroviral therapy. Lancet 1997;349(9063):1443-5.
6. Powderly WG, Landay A, Lederman MM. Recovery of the immune system with antiretroviral therapy: the end of opportunism? JAMA 1998;280(1):72-7.
7. Gulick RM, Mellors JW, Havlir D, Eron JJ, Gonzalez C, McMahon D, Richman DD, Valentine FT, Jonas L, Meibohm A, Emini EA, Chodakewitz JA. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 1997;337(11):734-9.
8. Richman DD. How drug resistance arises. Sci Am 1998;279(1):88.
9. Cunningham ET Jr, Margolis TP. Ocular manifestations of HIV infection. N Engl J Med 1998;339(4):236-44.
10. Belfort R Jr. The ophthalmologist and the global impact of the AIDS epidemic LV Edward Jackson Memorial Lecture. Am J Ophthalmol 2000;129(1):1-8.
11. De Cock KM, Lucas S, Coulibaly D, Coulibaly IM, Soro B. Expansion of surveillance case definition for AIDS in resource-poor countries. Lancet 1993;342(8868):437-8.
12. De Cock KM, Lucas SB, Lucas S, Agness J, Kadio A, Gayle HD. Clinical research, prophylaxis, therapy, and care for HIV disease in Africa. Am J Public Health. 1993;83(10):1385-9.
13. Bollinger RC, Tripathy SP, Quinn TC. The human immunodeficiency virus epidemic in India. Current magnitude and future projections. Medicine (Baltimore). 1995;74(2):97-106.
14. Mohar A, Romo J, Salido F, Jessurun J, Ponce de Leon S, Reyes E, Volkow P, Larraza O, Peredo MA, Cano C. The spectrum of clinical and pathological manifestations of AIDS in a consecutive series of autopsied patients in Mexico. AIDS. 1992;6(5):467-73.
15. Jessurun J, Angeles-Angeles A, Gasman N. Comparative demographic and autopsy findings in acquired immune deficiency syndrome in two Mexican populations. J Acquir Immune Defic Syndr 1990;3(6):579-83.
16. Muccioli C, Belfort R Jr. Presumed ocular and central nervous system tuberculosis in a patient with the acquired immunodeficiency syndrome. Am J Ophthalmol 1996;121(2):217-9.
17. Holland GN, Tufail A, Jordan MC. Cytomegalovirus diseases. In Pepose JS, Holland GN, Wilhelmus KR, editors. Ocular infection and immunity. St Louis: Mosby,1996:1088-1129.
18. Jabs DA, Bartlett JG. AIDS and ophthalmology: a period of transition. Am J Ophthalmol 1997;124(2):227-33.
19. Lalezari J, Lindley J, Walmsley S, et al. A safety study of oral valganciclovir maintenance treatment of cytomegalovirus retinitis. J Acquir Immune Defic Syndr 2002;30:392-400.
20. Martin DF, Sierra-Madero J, Walmsley S, et al. A controlled trial of valganciclovir as induction therapy for cytomegalovirus retinitis. N Engl J Med 2002;346:1119-26.
21. Diaz-Suarez O, Estevez J, Garcia M, Cheng-Ng R, Araujo J, Garcia M. [Seroepidemiology of toxoplasmosis in a Yucpa Amerindian community of Sierra de Perija, Zulia State, Venezuela] Rev Med Chil. 2003;131(9):1003-10.
22. Lopez JS, de Smet MD, Masur H, Mueller BU, Pizzo PA, Nussenblatt RB. Orally administered 566C80 for treatment of ocular toxoplasmosis in a patient with the acquired immunodeficiency syndrome. Am J Ophthalmol 1992;113(3):331-3.
23. Silveira C, Belfort R Jr, Muccioli C, Holland GN, Victora CG, Horta BL, Yu F, Nussenblatt RB. The effect of long-term intermittent trimethoprim/sulfamethoxazole treatment on recurrences of toxoplasmic retinochoroiditis. Am J Ophthalmol. 2002;134(1):41-6.
24. Karavellas MP, Lowder CY, Macdonald C, et al. Immune recovery vitritis associated with inactive cytomegalovirus retinitis: a new syndrome. Arch Ophthalmol 1998;116:169-75.
25. Arevalo JF, Mendoza AJ, Ferretti Y. Immune recovery uveitis in AIDS patients with cytomegalovirus retinitis treated with highly active antiretroviral therapy in Venezuela. Retina 2003;23:495-502.
26. Montaner JS, Hogg RS, Weber AE, Anis AH, O'Shaughnessy MV, Schechter MT. The costs of triple-drug anti-HIV therapy for adults in the Americas. JAMA. 1998;279(16):1263-4.
|
